Pomalyst is the brand name for pomalidomide, an oral immunomodulatory agent (IMiD) manufactured by Bristol Myers Squibb. FDA approved Pomalyst on February 8, 2013 (NDA 204026) for adult patients with relapsed or refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor. Pomalyst is also approved for AIDS-related Kaposi sarcoma following failure of highly active antiretroviral therapy and for HIV-negative adult patients with Kaposi sarcoma. Pomalidomide belongs to the same immunomodulatory drug class as thalidomide and lenalidomide (Revlimid), and all three carry the same REMS-based distribution requirement due to the risk of serious birth defects.
Pomalyst carries one of the highest retail price tags of any oral oncology drug, running approximately $24,476 per 21-capsule cycle in 2026 through REMS-certified specialty pharmacies. The standard dosing is 4 mg orally once daily on days 1 through 21 of each 28-day cycle in combination with low-dose dexamethasone. Because Pomalyst is a REMS-restricted product, it is not available at retail chain pharmacies like CVS or Walgreens; all dispensing flows through specialty pharmacy networks such as CVS Specialty, Accredo, Optum Specialty, and Humana Pharmacy. Starting in March 2026, multiple generic manufacturers including Breckenridge Pharmaceutical (with NATCO Pharma) and Camber Pharmaceuticals launched FDA-approved generic pomalidomide capsules, creating the first real price competition for this molecule. Generic pomalidomide currently runs approximately 15 to 30 percent below brand Pomalyst list price at specialty pharmacies, though the actual out-of-pocket cost for insured patients may differ depending on formulary tier placement and copay assistance availability.
The Inflation Reduction Act of 2022 selected pomalidomide (Pomalyst) for the second round of Medicare drug price negotiation, alongside enzalutamide (Xtandi), palbociclib (Ibrance), and acalabrutinib (Calquence). CMS announced a negotiated Maximum Fair Price of $8,650 per 30-day supply for Pomalyst, effective January 1, 2027. That represents approximately a 65 percent reduction from the 2026 list price. Between November 2023 and October 2024, approximately 14,000 Medicare Part D beneficiaries used Pomalyst, making it one of the highest-spend oncology drugs in the Medicare program. Patients on Medicare Part D today benefit from the $2,100 annual out-of-pocket cap in 2026, which limits total spending across all Part D drugs regardless of how expensive any individual drug is.
What Pomalyst Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same pomalyst can cost many times more at a hospital than at your local pharmacy:
2026 Pomalyst Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Specialty pharmacy (retail, cash, brand) | $24,476 - $26,000 per cycle | 21-capsule cycle through REMS-certified specialty pharmacy, without any insurance or discount. Available at CVS Specialty, Accredo, Optum Specialty, Humana Pharmacy, and similar networks only. |
| Generic pomalidomide (specialty pharmacy, cash) | $17,000 - $21,000 per cycle (est., 2026) | Breckenridge, Camber, and Aurobindo generics launched March 2026. Still a REMS product distributed through specialty pharmacies. 15 to 30 percent below brand list price. |
| Medicare Part D (2026) | $0 after $2,100 annual OOP cap | Pomalyst is a Part D specialty drug. Most Medicare Part D plans place it on Tier 5 (specialty). Your total out-of-pocket across all Part D drugs is capped at $2,100 per year in 2026; once reached, covered drugs including Pomalyst cost $0. |
| Commercial insurance with BMS Access Support copay card | $0 - $10 per cycle (up to $15,000/year benefit cap) | For commercially insured patients only. The BMS Access Support Co-Pay Assistance Program limits patient cost to as little as $0 to $10 per one-month supply. Government insurance (Medicare, Medicaid, TRICARE, VA) is excluded by federal anti-kickback law. |
| Medicaid | $1 - $4 per prescription (with prior authorization) | Medicaid covers Pomalyst for multiple myeloma with prior authorization. State Medicaid programs set their own nominal copay, typically $1 to $4 per fill. |
Specialty pharmacy prices reflect 2026 list pricing for brand Pomalyst and estimated generic pomalidomide ranges after March 2026 launch. Actual patient cost depends on insurance, formulary tier, copay assistance enrollment, and where you are in your Part D benefit year.
Source: Bristol Myers Squibb Pomalyst list pricing, CMS Part D 2026 benefit parameters, BMS Access Support program terms, GoodRx specialty drug pricing
Why Hospitals Charge So Much
Pomalyst is an oral outpatient drug taken at home, which means inpatient hospital charges for Pomalyst are uncommon. When they do appear on a hospital bill, it is usually because the inpatient pharmacy dispensed a partial supply during an admission for a complication of multiple myeloma, such as infection, fracture, or renal failure. In that scenario, hospital pharmacies apply the same facility-rate markup structure that governs all inpatient drug charges, adding overhead, handling, and administrative fees on top of the acquisition cost. A 21-capsule supply acquired by the hospital at the specialty pharmacy acquisition price near $24,000 can appear on an itemized inpatient bill at $30,000 to $55,000, reflecting 25 to 130 percent facility markup above acquisition cost.
Patients who receive a hospital bill showing Pomalyst charges above $30,000 per cycle should request an itemized line-item bill and compare the NDC-level acquisition cost to the billed amount. The NDC codes for brand Pomalyst are 59572-0501-21 (1 mg), 59572-0502-21 (2 mg), 59572-0503-21 (3 mg), and 59572-0504-21 (4 mg), all in 21-count bottles. Facility markups far beyond the specialty pharmacy acquisition cost can be disputed with the hospital's patient accounts department, especially when the standard of care is outpatient oral administration at home rather than inpatient dispensing. Most commercial insurance contracts limit reimbursement to the outpatient pharmacy rate, which means excessive inpatient Pomalyst charges often fall to the patient balance unless disputed.
Multiple myeloma itself is associated with very high per-patient per-month treatment costs, estimated at approximately $35,657 per month across all myeloma-related expenses in published analyses. When a patient is admitted to the hospital for a myeloma-related complication while on Pomalyst, the combination of facility fees, supportive-care medications, and the Pomalyst charge itself can push the itemized bill well above $50,000 for a short stay. Requesting an itemized bill, identifying any duplicate charges for the same drug cycle, and using the medical bill analyzer at coveredusa.org can reveal overbilling patterns worth disputing.
Patient Assistance Programs
Bristol Myers Squibb operates two distinct programs that can dramatically lower Pomalyst cost depending on your insurance status. The BMS Access Support Co-Pay Assistance Program is a manufacturer coupon-style program that targets commercially insured patients; the Bristol Myers Squibb Patient Assistance Foundation (BMSPAF) targets uninsured patients who cannot afford the drug. A third option, the HealthWell Foundation Multiple Myeloma Medicare Access fund, helps Medicare beneficiaries cover Part D cost-sharing. Without any assistance program, the retail cash price for Pomalyst runs near $24,476 per cycle, which is the baseline you are comparing against when evaluating which patient assistance program to pursue.
Patient assistance programs for Pomalyst| Manufacturer program | Cost / Benefit | How to apply |
|---|
| BMS Access Support Co-Pay Assistance Program (Commercially Insured) | $0 to $10 per one-month supply, up to $15,000 maximum benefit per calendar year | bmsaccesssupport.com |
| Bristol Myers Squibb Patient Assistance Foundation (BMSPAF) | Free Pomalyst for uninsured patients with household income at or below 400% of the federal poverty level | bmspaf.org or call 1-800-736-0003 |
| HealthWell Foundation Multiple Myeloma Medicare Access Fund | Up to $8,000 per year for Medicare Part D copay and premium assistance; income up to 500% FPL | healthwellfoundation.org or call 1-800-675-8416 |
| NeedyMeds Drug Discount Database | Directory of additional manufacturer, foundation, and pharmacy discount programs for pomalidomide | needymeds.org |
Manufacturer copay assistance cards (BMS Access Support) are not available to Medicare, Medicaid, TRICARE, or VA beneficiaries by federal anti-kickback statute (42 U.S.C. 1320a-7b). If you have any government health insurance, apply for the BMSPAF free-drug program or the HealthWell Foundation fund instead. The BMSPAF and HealthWell programs are legally separate from Bristol Myers Squibb and may be used by Medicare patients.
Source: Bristol Myers Squibb BMS Access Support, bmspaf.org, HealthWell Foundation, NeedyMeds.org
Medicare Part D
Pomalyst is a Medicare Part D specialty drug. For 2026, the Inflation Reduction Act caps your total annual out-of-pocket spending on all Part D drugs combined at $2,100. Given Pomalyst's list price of approximately $24,476 per cycle, most Medicare patients will hit the $2,100 annual cap quickly, usually within the first one or two cycles of the benefit year, after which Pomalyst costs $0 for the remainder of the calendar year. Once enrolled in a Medicare Part D plan that covers Pomalyst, ask your plan about the Medicare Prescription Payment Plan, which lets you spread your Part D out-of-pocket costs evenly across 12 monthly installments instead of paying a large amount in the early months of the year.
Medicare Part D plans typically place Pomalyst on the highest tier, Tier 5 specialty, which carries the highest coinsurance percentage before you hit the out-of-pocket cap. However, because the annual out-of-pocket cap of $2,100 kicks in relatively quickly for a drug at this price point, the tier-5 coinsurance rate primarily affects how fast you reach the cap rather than your total annual exposure. Prior authorization is standard for Pomalyst on Medicare Part D; most plans require documentation of at least two prior lines of multiple myeloma therapy including a proteasome inhibitor and lenalidomide. If your plan denies Pomalyst, you have the right to appeal and request a formulary exception based on medical necessity. You can also apply for Medicare Extra Help (Low Income Subsidy) if you qualify, which substantially reduces your Part D cost-sharing and delays reaching the annual cap.
Starting January 1, 2027, the Inflation Reduction Act Maximum Fair Price of $8,650 per 30-day supply takes effect for Medicare beneficiaries, representing approximately a 65 percent reduction from the 2026 list price. This is a direct result of CMS negotiations with Bristol Myers Squibb under the Medicare Drug Price Negotiation Program established by the Inflation Reduction Act of 2022. Patients on Medicare Part D in 2027 will still benefit from the annual out-of-pocket cap (which will be re-indexed for 2027), but the lower Maximum Fair Price means the plan's spending also decreases, which should reduce premiums over time. Patients who pay cash for Pomalyst today and do not have Medicare will not receive the IRA Maximum Fair Price benefit; that price applies only to Medicare Part D claims.
Common Pomalyst Billing Errors
Pomalyst has a complex billing profile because it is a specialty drug distributed under REMS, requires prior authorization, and generic versions now exist. If you received a bill for Pomalyst that seems higher than expected, check for these issues before paying:
- Prior authorization expired or was not renewed before the next cycle. Many plans require PA renewal every 6 to 12 months for Pomalyst. A lapsed PA can result in the pharmacy dispensing the drug at cash price, creating a bill near $24,000 instead of your plan copay.
- Brand Pomalyst dispensed when generic pomalidomide was prescribed (or vice versa), causing a formulary tier mismatch and higher cost-sharing than expected.
- BMS Access Support copay card not applied at the specialty pharmacy even though the patient is commercially insured and enrolled. Ask the specialty pharmacy to confirm the copay card BIN/PCN is on file before each cycle.
- Billed at the full $24,476 list price after the $2,100 Part D annual out-of-pocket cap was already met for the calendar year. Once you reach the cap, your plan should cover Pomalyst at $0.
- REMS certification gap at the dispensing specialty pharmacy. All pharmacies must be enrolled in the POMALYST REMS program. If a claim is rejected for an uncertified pharmacy, the patient may be billed directly. Confirm your specialty pharmacy is REMS-certified before each fill.
- Inpatient hospital charge for Pomalyst far exceeding the specialty pharmacy acquisition cost, without documentation of medical necessity for inpatient dispensing rather than outpatient take-home supply.
Frequently Asked Questions
Is there a generic for Pomalyst (pomalidomide) in 2026?
Yes. Generic pomalidomide capsules launched commercially in March 2026, with Breckenridge Pharmaceutical (NATCO Pharma partnership), Camber Pharmaceuticals, and Aurobindo's Eugia arm all entering the market. Generic pomalidomide is FDA-approved as bioequivalent to brand Pomalyst in all four strengths (1 mg, 2 mg, 3 mg, 4 mg). However, generic pomalidomide remains a REMS-restricted product, meaning it is dispensed only through certified specialty pharmacies, not at retail chains. The generic list price runs approximately 15 to 30 percent below brand Pomalyst in 2026. Patients should ask their oncologist and specialty pharmacy whether switching to generic pomalidomide preserves their copay assistance eligibility.
How do I apply for the Bristol Myers Squibb Patient Assistance Foundation for Pomalyst?
Visit bmspaf.org or call 1-800-736-0003 to start. You need to complete the BMSPAF application form (patient and prescriber sections), provide proof of household income at or below 400 percent of the federal poverty level (up to $63,840 for a household of one in 2026), proof of US residency, a valid Pomalyst prescription, and written confirmation that you have no prescription drug insurance. Your oncologist must sign the prescriber section. Submit by fax or through the online portal. Processing takes 7 to 14 business days. If approved, Pomalyst ships free to your home or your doctor's office in 90-day supplies, renewable annually.
Can I use the BMS copay card for Pomalyst if I have Medicare?
No. The BMS Access Support Co-Pay Assistance Program for Pomalyst is available only to commercially insured patients. Federal anti-kickback statute (42 U.S.C. 1320a-7b) bars manufacturer copay cards from being used by anyone enrolled in Medicare, Medicaid, TRICARE, or VA benefits. If you have Medicare Part D, your options are the $2,100 annual out-of-pocket cap in 2026 (which limits your total Part D spending), Medicare Extra Help if you qualify, and the HealthWell Foundation Multiple Myeloma Medicare Access Fund, which provides up to $8,000 per year and is legally separate from Bristol Myers Squibb.
Does the IRA negotiated price apply to Pomalyst in 2026?
Not yet. Pomalyst was selected for the second round of IRA Medicare drug price negotiation, but the Maximum Fair Price of $8,650 per 30-day supply takes effect January 1, 2027, not in 2026. For 2026, Medicare Part D patients pay based on their plan's formulary tier coinsurance until the $2,100 annual out-of-pocket cap is reached, after which Pomalyst costs $0. Starting in 2027, Medicare beneficiaries pay based on the $8,650 Maximum Fair Price, a 65 percent reduction from the 2026 list price of approximately $24,476 per cycle.
What does Pomalyst cost without insurance at the pharmacy in 2026?
Without insurance, brand Pomalyst costs approximately $24,476 per 21-capsule cycle through REMS-certified specialty pharmacies in 2026. Generic pomalidomide, which launched in March 2026, runs roughly $17,000 to $21,000 per cycle. Pomalyst is not available at retail chains like Walmart or Walgreens; all dispensing is through specialty pharmacy networks such as CVS Specialty, Accredo, and Optum Specialty. GoodRx-type discount programs show prices as low as $4,309 to $6,500 for Pomalyst, but these figures may reflect partial cycle quantities or estimates rather than full 21-capsule cycle pricing. The Bristol Myers Squibb Patient Assistance Foundation can provide free Pomalyst to uninsured patients below 400 percent of FPL.
Do I qualify for the Pomalyst patient assistance program?
The Bristol Myers Squibb Patient Assistance Foundation (BMSPAF) requires three conditions: you must be a US resident, you must be treated as an outpatient by a US-licensed prescriber, and you must have no prescription drug insurance coverage for Pomalyst. Income must be at or below 400 percent of the federal poverty level, which is $63,840 for a household of one, $86,560 for two, $132,000 for four, and $222,880 for eight people in 2026. The HealthWell Foundation Multiple Myeloma Medicare Access Fund has a higher income limit of 500 percent FPL and specifically helps Medicare patients with cost-sharing up to $8,000 per year.
What if my insurance denies coverage for Pomalyst?
Start by requesting a written denial with the specific reason. Ask your oncologist to file a peer-to-peer review with the plan's medical director, presenting the clinical rationale under NCCN guidelines for pomalidomide in relapsed or refractory multiple myeloma after prior lenalidomide and proteasome inhibitor exposure. If the internal appeal is denied, escalate to an Independent Review Entity (Medicare) or your state Department of Insurance (commercial plans). While appeals are pending, contact BMSPAF (1-800-736-0003) and the HealthWell Foundation (1-800-675-8416) for immediate assistance. Also consider whether generic pomalidomide is on a preferred formulary tier at lower cost-sharing.
What is the difference between Pomalyst and Revlimid (lenalidomide)?
Both Pomalyst (pomalidomide) and Revlimid (lenalidomide) are immunomodulatory drugs in the IMiD class, made by Bristol Myers Squibb. Revlimid is typically used in earlier lines of multiple myeloma therapy, while Pomalyst is specifically approved for patients who have already received lenalidomide and a proteasome inhibitor and have relapsed or refractory disease. Revlimid lost patent protection and generic lenalidomide is widely available at substantially lower prices. Pomalyst only recently saw generic competition in March 2026. From a cost standpoint in 2026, generic lenalidomide is dramatically cheaper at specialty pharmacies, while generic pomalidomide still runs $17,000 to $21,000 per cycle as the generics market is still establishing pricing.
